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Genome-wide association studies (GWAS) have repeatedly identified genetic variants 
associated with bone mineral density (BMD) and osteoporotic fracture in non-coding 
regions of C7ORF76, a poorly studied gene of unknown function. The aim of the 
present study was to elucidate the causality and molecular mechanisms underlying the 
association. We re-sequenced the genomic region in two extreme BMD groups from 
the BARCOS cohort of postmenopausal women to search for functionally relevant 
variants. Eight selected variants were tested for association in the complete cohort and 
2 of them (rs4342521 and rs10085588) were found significantly associated with lumbar 
spine BMD and nominally associated with osteoporotic fracture. cis-eQTLs analyses of 
these 2 SNPs, together with SNP rs4727338 (GWAS lead SNP in Estrada et al., Nat 
Genet. 44:491-501, 2012), performed in human primary osteoblasts, disclosed a 
statistically significant influence on the expression of the proximal neighbouring gene 
SLC25A13 and a tendency on the distal SHFM1. We then studied the functionality of a 
putative upstream regulatory element (UPE), containing rs10085588. Luciferase 
reporter assays showed transactivation capability with a strong allele-dependent effect. 
Finally, 4C-seq experiments in osteoblastic cell lines showed that the UPE interacted 
with different tissue-specific enhancers and a lncRNA (LOC100506136) in the region.  
In summary, this study is the first one to analyse in depth the functionality of C7ORF76 
genomic region. We provide functional regulatory evidence for the rs10085588, which 























Genome-wide association studies (GWAS) have been successfully used to identify 
genetic variants associated with complex traits and diseases, such as osteoporosis. In 
a few cases, the associated SNPs are located within a coding region of a gene, 
facilitating its functional evaluation. However, the vast majority of associated SNPs lie 
in non-coding regions, which make it challenging to understand the functional 
mechanisms underlying the association [1,2]. In addition, it is highly probable that the 
associated SNPs are in linkage disequilibrium (LD) with the causal variant.  
To date, many GWAS have been performed to find genetic association with bone 
mineral density (BMD) and osteoporotic fracture [3–12]. BMD is a genetically 
determined, extensively measured quantitative trait (heritability of 0.5-0.85) and, 
therefore, a good marker for bone status. Low-trauma fracture, the clinical outcome of 
osteoporosis, is also heritable, albeit to a lesser extent (heritability of 0.54-0.68) [13]. 
These GWAS have identified more than 500 candidate loci [12], although the causal 
variants remain largely unknown. In addition, all the GWAS findings together only 
explain a small proportion (~20%) of the total genetic impact on BMD [12]. Some 
associated loci contain genes not previously known to play a role in bone biology, 
which is the case of C7ORF76 (AKA FLJ42280, currently annotated as transcript 
variant 6 of gene SEM1 in GRCh38), in the 7q21.3 genomic region. Several SNPs 
within this region have been found significantly associated with both lumbar spine (LS) 
and femoral neck (FN) BMD as well as with osteoporotic fracture in different GWAS 
and meta-analyses [4,6–8,14–16]. In particular, in the largest meta-analysis carried out 
so far [7], the lead SNP of this locus (rs4727338) was one of the genome-wide top-
associated signals. Yet, C7ORF76 is a poorly studied gene of unknown function and 















In this study, we aimed at elucidating the causality and molecular mechanisms 
underlying the strong association identified in the C7ORF76 genomic region. We have 
deeply re-sequenced the genomic region in two extreme BMD groups of 
postmenopausal women of the BARCOS cohort and selected some variants to analyse 
their association in the full cohort. Through a combination of several in silico and 
experimental approaches, we studied a possibly causal SNP located in a regulatory 
region and demonstrated its functionality.  
 
 
2. MATERIAL AND METHODS 
2.1. Study Cohort 
The BARCOS cohort consisted of 1490 postmenopausal women of Spanish descent 
from the Barcelona area, monitored at the Hospital del Mar (Barcelona, Spain). 
Exclusion criteria were any history of bone diseases, metabolic or endocrine disorders, 
hormone-replacement therapy, or use of drugs that could affect bone mass. BMD of all 
participants was measured at LS and FN by dual energy X-ray absorptiometry (DXA). 
The following data were also recorded: age, age of menarche and menopause, number 
of fractures and anthropometric measures such as weight and height. DNA is available 
from all samples of the cohort. Details of the cohort and DNA extraction have been 
described previously [17,18]. Written informed consent was obtained from all patients 
in accordance with the regulations of the Clinical Research Ethics Committee of Parc 
de Salut Mar, which approved the study. All experiments and protocols were approved 
by the Bioethics Committee of Universitat de Barcelona (IRB00003099). 
For the re-sequencing of the C7ORF76 locus, two extreme LS-BMD groups were 
selected from the BARCOS cohort, using the statistical Z-score. The 50 women with 
the highest Z-score values (from 2.98 to 0.73) were included in the 50-H group and the 

















Re-sequencing of the C7ORF76 (ENSG00000197851; ENST00000356686.1) genomic 
region was performed in the 100 individuals of the two extreme subgroups of the 
BARCOS cohort, according to the Z-score. A 28 kb region (chr7:96,108,695-
96,136,619; GRCh37), including the C7ORF76 gene and the 3.8 kb upstream and 2 kb 
downstream regions of the gene, was amplified in 7 overlapping fragments by Long 
Range-PCR (Supplementary Table 1). All amplicons were purified and quantified using 
the Quant-iT PicoGreen dsDNA Reagent and Kit (Life Technologies, Thermo Fisher) 
before pooling them equimolarly into two groups, one of HBM and another of LBM. 
Both pools were tagged with a MID adaptor and an emulsion-PCR was carried out prior 
to massive parallel sequencing at 3600x coverage per pool with Roche’s 454 GS 
Junior System. The massive parallel sequencing was carried out in the Genomics 
facilities of the Universitat de Barcelona. The raw data obtained were processed to trim 
the MIDs, using a custom pipeline, and were mapped against the reference genome 
(GRCh37), using the GS Mapper software (Roche). Mapped reads were filtered, sorted 
and indexed using SAMtools [19]. Single Nucleotide Variants (SNVs) and indels were 
identified using GATK standard hard filtering parameters [20]. The variants were 
filtered according to the following criteria: coverage ≥ 1.000 reads, variants present in ≥ 
1% of the reads per pool and low strand bias. The number of reads of a variant was 
normalised with its coverage and the variants were classified according to minor allele 
frequency (MAF): Common (MAF ≥ 5%), and lower frequency variants (MAF <5%). The 
variants were validated either by differential digestion with restriction enzymes or by 
high resolution melting, using the Light Cycler® 480 ResoLight Dye (Roche). 
 
2.3. In silico functional analyses and motif analysis 
In silico functional analyses consisted in annotating the European and Iberian MAF of 














pathogenicity of exonic variants, using SIFT [21], PolyPhen [22] and Mutation Taster 
[23]; and, for the intronic variants, analysing the DNase I hypersensitivity, histone 
modifications, transcription factor binding, miRNAs binding, etc. of the regions of 
interest. All the in silico data was obtained from ENCODE [24], International Human 
Epigenome Consortium [25], The Roadmap Epigenomics Project, FANTOM5 [26], 
HaploReg [27], RegulomeDB [28], miRTarBase [29], miRdSNP [30], MirSNP [31], 
BioMart, and Ensembl and UCSC Genome Browser. All variants were analysed with 
the Variant Effect Predictor from Ensembl, the Variant Annotation Integrator from 
UCSC, and FuncPred from the National Institute of Environmental Health Sciences. 
Transcription factor binding sites prediction considering the different alleles of the 
variants was done using MatInspector [32] and the Bioconductor “motifbreakR” 
package (https://bioconductor.org/packages/release/bioc/html/motifbreakR.html) [33] 
using default method settings (weighted sum) and a p-value cut-off at 5x10-5 for SNPs. 
Super-enhancer data was obtained from a catalogue of super-enhancers in 86 human 
cell and tissue samples [34] and from SEdb [35]. 
 
2.4. SNV Genotyping 
Genotyping of 8 selected variants in the complete BARCOS cohort was carried out at 
LGC Genomics (Hoddesdon, UK). In addition, as BARCOS was included in the 
replication phase of the meta-analysis by Estrada et al. [7], the genotyping results of 
the SNP rs4727338 were also available. The genotyping of 6% of the samples was 
performed in duplicate, as a genotyping quality control, and showed a concordance 
above 99%. 
 
2.5. Linkage Disequilibrium Analysis 
The Haploview software [36] was used to calculate and represent the degree of linkage 















2.6. Cell culture 
The human osteosarcoma cell line Saos-2 was used for luciferase reporter assays and 
4C-seq assays. It was obtained from the American Type Culture Collection (ATCC® 
HTB-85TM) and grown in Dulbecco’s Modified Eagle Medium (DMEM; Sigma-Aldrich), 
supplemented with 10% Fetal Bovine Serum (FBS; Gibco, Life Technologies) and 1% 
penicillin/streptomycin (Gibco, Life Technologies), at 37ºC and 5% of CO2. Human fetal 
osteoblasts (hFOB) 1.19 cells were used for 4C-seq assays. They were obtained from 
ATCC (ATCC® CRL-11372TM) and grown in DMEM:F12 (1:1) medium without phenol 
red (Gibco, Life Technologies), supplemented with 10% FBS and 0.3mg/ml Geneticin 
(Gibco, Life Technologies), at 34ºC and 5% of CO2. Human medulla-derived 
mesenchymal stem cells (MSCs) were also used for 4C-seq assays. They were kindly 
provided by Dr. José Manuel Quesada Gómez, from Instituto Maimónides de 
Investigación Biomédica, Hospital Universitario Reina Sofía, Córdoba, Spain. They 
were grown in alpha-MEM medium (Gibco, Life Technologies), supplemented with 10% 
FBS, 1% penicillin/streptomycin and 1x Glutamax (Gibco, Life Technologies), at 37ºC 
and 5% of CO2. Human primary osteoblasts (hOB) were used for eQTL assays. They 
were obtained from trabecular bone of women who underwent knee replacement due 
to osteoarthritis and who did not have any other pathology that could affect the bone 
status. Bony tissue was cut up into small pieces, washed in phosphate buffered saline 
(PBS; Gibco, Life technologies) to remove non-adherent cells, and placed on a 140 
mm culture plate. Samples were cultured in DMEM supplemented with 10% FBS, 100 
U/ml penicillin/streptomycin, 0.4% fungizone (Gibco, Life Technologies) and 100 g/ml 
ascorbic acid (Sigma-Aldrich). DNA and RNA extractions were performed at maximum 
passage 2. HeLa and HEK293 cell lines were obtained from ATCC (ATCC® HTB-85 
and ATCC® CCL-2TM, respectively) and grown in DMEM supplemented with 10% FBS 
and 1% penicillin/streptomycin at 37ºC and 5% CO2. 
 














DNA was extracted from cultured hOBs using the Wizard® Genomic DNA Purification 
Kit (Promega), according to manufacturer’s instructions. The concentration of the 
purified DNA was analysed in a spectrophotometer (Nanodrop). Genotypes for 
rs4727338, rs10429035, rs12674052, rs4342521, and rs10085588 were assessed by 
Sanger sequencing using the BigDye® Terminator v3.1 (Applied Biosystems) in the 
Genomics facilities of Universitat de Barcelona. Primers (Invitrogen, Thermo Fisher) 
were designed using the Primer3 Input 0.4.0 (Supplementary Table 2). 
 
2.8. Human primary osteoblasts RNA extraction, retrotranscription and qPCR 
RNA was extracted from cultured hOBs using the High Pure RNA Isolation kit (Roche), 
according to manufacturer’s instructions. RNA was quantified using a Nanodrop 
spectrophotometer and retrotranscribed using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Thermo Fisher), according to the specifications 
of the manufacturer. qPCR was performed using UPL Probes (Roche) on a LightCycler 
480 Instrument II (Roche). Expression of HMBS was used as a normalizing control, 
and fold changes (FC) were calculated by relative quantification, using the 2nd 
derivative method. Primers used to amplify the neighbouring genes of the C7ORF76 
locus are summarised in Supplementary Table 3. 
 
2.9. Amplification of an UPstream regulatory Element (UPE)-derived transcript  
UPE-derived transcript was amplified from HeLa, HEK293, human primary osteoblasts 
and Saos-2 cDNA (200 ng) by PCR, using the following primers: 5’-
CACTTTTTCAAATCCCACCTG-3’ and 5’-TGAGAGCTGCTTAGAAATGGAA-3. PCR 
products were run in a 2% agarose gel. 
 
2.10. Luciferase reporter constructs and site-directed mutagenesis 
The 750 bp-fragment containing the UPE was PCR-amplified from human genomic 














TGAGAGCTGCTTAGAAATGGAA-3’, and cloned in both orientations using XhoI and 
KpnI restriction enzymes in the pGL3-Basic vector (Promega). The minor allele of the 
rs10085588 (A) was introduced with the QuikChange Lightning Site-Directed 
Mutagenesis Kit (Agilent), following the manufacturer instructions. All the plasmids 
were validated by Sanger sequencing. 
 
2.11. In vitro luciferase assay 
Saos-2 cells were seeded at a density of 3.0x105 cells per well in a 6-well plate. After 
24h, they were transfected with 2.2 µg of total DNA per well using FuGENE HD reagent 
(Promega), according to manufacturer instructions. Two plasmids were cotransfected 
in each well: the pGL3-Basic empty or with the UPE fragment cloned upstream of the 
Firefly Luciferase coding region and the pRL-TK plasmid, containing the Renilla 
Luciferase gene, in a proportion of 1/10. Forty-eight hours after transfection, cells were 
rinsed with PBS and lysed. The luciferase activity was measured using a Glomax 
Multi+ luminometer (Promega), with the Dual-Luciferase® Reporter Assay System 
reagents (Promega). Each experiment was performed in two biological replicates and 
was repeated 5 times. 
 
2.12. 4C-seq 
4C-seq was carried out at the Functional Genomics Service of the Centro Andaluz de 
Biología del Desarrollo (Sevilla, Spain). 4C-seq libraries were generated from Saos-2, 
hFOB 1.19 and hMSCs lines as described previously [37,38]. 4-bp cutters were used 
as primary (DpnII) and secondary (Csp6I) restriction enzymes. For each cell line, a 
total of 1.6 µg of library was amplified by PCR (primers used: 
CTGGAAGAGTCCCAGGGATC and AATGGAAGAGTGGAGATTCAGG; 
chr7:96,137,244-96,137,535). Samples were sequenced with Illumina Hi-Seq 
technology according to standard protocols at the Genomics Service of the Centro 














analysed as described previously [39]. Briefly, raw sequencing data were 
demultiplexed and mapped to the corresponding reference genome (GRCh37). Reads 
located in fragments flanked by two restriction sites of the same enzyme, in fragments 
smaller than 40 bp or within a window of 10 kb around the viewpoint were filtered out. 
4C-seq data were normalised by the total weight of reads within ±2 Mb around the 
viewpoint. The experiments were carried out in one biological replicate. 
 
2.13. Topologically associating domain (TAD) analysis 
TAD data on different cell types from Dixon et al. [40] was collected from the 3D 
Genome Browser (http://promoter.bx.psu.edu/hi-c/) [41] and displayed using the UCSC 
Genome Browser. The 3D Genome Browser was also used to visualise published Hi-C 
data.  
 
2.14. Statistical methods 
Statistical analyses were performed using the R software version 3.4.1. Hardy-
Weinberg equilibrium (HWE) was calculated using Chi-square test and p-values <0.01 
were considered significant. Fisher’s exact test with Bonferroni correction for multiple 
testing was used to statistically compare the differences of the genotype frequency of 
the common variants in each extreme group (HBM and LBM). Linear regression 
analysis adjusted by years since menopause (YSM) was performed to determine the 
association between BMD and the genotype of each SNV in the complete BARCOS 
cohort. Linear regression was also used to assess the association between gene 
expression levels and genotypes (cis-eQTL) in primary osteoblasts. All analyses were 
performed using the SNPassoc package testing the additive, recessive and dominant 
model. p-values<0.05 were considered significant. Correction for multiple testing was 
performed using the Bonferroni’s method for the number of SNPs tested.  
Relative luciferase units (RLU, i.e. the ratio of the firefly luciferase activity over the 














way blocked ANOVA with TukeyHSD post-hoc test was performed. All the data was 
ascertained for normality, homoscedasticity and atypical data points and p-values<0.05 




3.1. Re-sequencing of C7ORF76 locus in extreme BMD groups of the BARCOS cohort 
and variant functional annotation 
We re-sequenced 28 kb of the C7ORF76 genomic region (chr7:96,108,695-
96,136,619; GRCh37) in the 50 women with the highest and 50 women with the lowest 
LS-BMD of the BARCOS cohort (Fig. 1). Total number and location of single nucleotide 
variants (SNVs) detected before and after filtering and validating are shown in Table 1. 
Fifty-one common variants (MAF above 5%) and 59 lower frequency variants (MAF 
below 5%) were identified. The lower frequency variants were equally distributed 
between both extreme groups. To better assess the importance of the variants, we 
explored their functionality using publicly available in silico data (transcription factor 
binding, DNase I hypersensitivity, conservation, miRNAs binding, and histone marks). 
Twenty-eight variants were found in putative regulatory regions, 4 of which were 
located in osteoblast regulatory regions (rs9785005, rs10238953, rs4613908 and 
rs117923361) and 1 of them (rs4613908) was found in an active osteoblast enhancer. 
One missense variant was also identified but it was predicted to be tolerated by SIFT, 
to be benign by Polyphen and to be a polymorphism according to MutationTaster. 
None of the variants was predicted to affect miRNAs binding. Only 1 variant 
(rs4342521) showed nominal significance between the genotype frequencies of the two 
extreme groups (Fisher’s exact test, p=0.0382). This SNP is located 3 kb upstream of 
the C7ORF76 gene and the minor allele (T) was overrepresented in the LBM group. 
 














We selected 8 interesting variants, taking into consideration both frequency and 
functionality (Fig. 1), including 2 located in a putative regulatory region 4kb upstream of 
the C7ORF76 transcription start site (TSS), which we named UPE, that was not 
included in the re-sequencing. These 8 variants were genotyped in the complete 
BARCOS cohort (n=1490) to test their association with BMD and osteoporotic fracture. 
For all of them, we obtained MAF values similar to those found in the 1000 Genomes 
database for the European or Iberian populations (Supplementary Table 4). Significant 
differences were obtained with two of the 5’ upstream SNPs, rs4342521 and 
rs10085588 (Fig. 1), for LS-BMD under additive and recessive models and nominal 
differences were obtained with the same SNPs for osteoporotic fracture, under additive 
and dominant models (Table 2). In all cases, the minor allele (T and A, respectively) 
had a BMD-lowering effect on LS and had a damaging effect on osteoporotic fracture. 
The two associated SNPs were found to be in linkage disequilibrium with the GWAS hit 
(rs4727338) from Estrada et al. [7] (Fig. 2), which was also significantly associated with 
LS-BMD in the BARCOS cohort (Table 2). 
 
3.3. Cis-eQTL analyses 
To evaluate the functionality of the associated variants (rs4727338 –GWAS hit-, 
rs4342521 and rs10085588) we first tested them as cis-eQTLs in human primary 
osteoblasts, a cell type unavailable in GTEx. Of note, we failed to detect C7ORF76 
mRNA expression in these cells. None of the SNPs were found to be eQTLs for DLX5, 
DLX6, DLX6-AS1, or SHFM1 (SEM1 transcript variant 5 in GRCh38), although a 
tendency was observed for the latter (Table 3). On the contrary, the 3 SNPs were 
found nominally associated with SLC25A13 gene expression, where the minor alleles 
were associated with decreased gene expression. We also tested another SNP of the 
region (rs10429035) found associated with BMD in a previous GWAS meta-analysis [8] 














detect an association of this SNP with gene expression of any of the nearby genes 
(data not shown). 
 
3.4. Evaluation of the regulatory capability of the UPE 
Next, as the associated SNP rs10085588 is located in a putative regulatory region 4 kb 
upstream of the C7ORF76 gene (UPE; Fig. 1), we assessed the functionality of the 
UPE. We performed luciferase reporter assays in Saos-2 cells to test UPE activity in 
both orientations and the effects of the two alleles of rs10085588. As shown in Fig. 3A, 
the forward UPE construct bearing the major allele (G) showed significantly increased 
luciferase expression compared to the empty vector (FC: 5.3, p=0.0097), and 
compared to the construct bearing the minor allele (A) (FC: 11.6, p<0.001). No activity 
was detected when the UPE was tested in the inverse orientation (data not shown). 
Results of luciferase assays were consistent with eQTL analyses, in the sense that the 
minor allele (A) fails to activate transcription and is associated with lower expression of 
SLC25A13 in osteoblasts (see above). We also evaluated whether the UPE was 
transcribed (as occurs in many regulatory regions) by performing RT-PCR in cDNA of 
human primary osteoblasts, Saos-2, HeLa and HEK293 cells. We were able to amplify 
the UPE sequence from cDNA of HeLa, HEK293 and Saos-2 cells but we failed to 
amplify it from different cDNA samples of human primary osteoblasts (Fig. 3B). We 
also interrogated the FANTOM5 Cap Analysis of Gene Expression (CAGE) dataset [26] 
for evidence of UPE transcription and we could observe a signal for TSS expression in 
smooth muscle cells. 
 
3.5. Chromatin interactions from the UPE 
Finally, we investigated the possible genomic targets of the UPE by examining the 3D 
chromatin interactions by 4C-seq in different cell types (MSCs, hFOB 1.19 and Saos-
2). We detected interaction between UPE and the genomic region spanning 














detected elsewhere in the genome. Notably, we found higher interaction levels with 
most of the tissue-specific enhancers described in the VISTA browser [42,43], 
especially in the hFOB 1.19 cell line. We could also detect higher interaction with the 
long non-coding RNA gene LOC100506136, upstream of C7ORF76. In addition, we 
analysed the topologically associated domains (TADs) of the region on different cell 
types using available Hi-C data [40] and the 3D Genome Browser [41] and we 
observed that in many cell types, the TAD containing the gene C7ORF76 spanned 
from approximately 50 kb upstream of DYNC1I1 TSS to approximately 25 kb upstream 




Different non-coding variants in the C7ORF76 genomic region have been previously 
associated with BMD and osteoporotic fracture in different GWAS [4,6–8,14–16] and at 
this point, deciphering the functionality of this region would be the next logical step for 
understanding these associations. In this line, we have analysed the C7ORF76 region 
in depth, including re-sequencing, testing variants for association in the BARCOS 
cohort, and analysing the functionality of the variants and regulatory regions both in 
silico and experimentally. Two upstream variants (rs4342521 and rs10085588) were 
found significantly associated with LS-BMD and nominally associated with osteoporotic 
fracture. In addition, both SNPs have been identified as eQTLs of SLC25A13 in human 
primary osteoblasts. Moreover, the SNP rs10085588 falls in a regulatory region (UPE) 
able to stimulate transcription in an allele-dependent manner. This UPE was found to 
interact with different tissue-specific enhancers and a lncRNA present in the nearby 
region.  
The C7ORF76 gene is an uncharacterised gene of unknown function without 
expression data in GTEx. In the current human genome assembly (GRCh38) it is 














subunit, whose alternative historical name is SHFM1 for Split Hand and Foot 
Malformation 1). However, although RefSeq currently labels it as curated gene, 
surprisingly few data have been gathered and the real function of C7ORF76 remains 
elusive. This is in contrast with the consistent finding of potent GWAS signals for 
osteoporosis within this gene. Of note, this gene seems to be not expressed in primary 
osteoblasts, Saos-2, HeLa and SH-SY5Y (data not shown) which suggests that either it 
might, indeed, not be an osteoblast gene, yet regulate BMD from a different cell type or 
organ, or, alternatively, other genes in the region could be causal for the association. 
Most GWAS variants for complex diseases are located in non-coding regulatory 
regions (reviewed in Zhang et al. [44]) and several studies have pinpointed the 
importance of regulatory elements for the susceptibility to osteoporosis [45,46]. 
Moreover, for some common traits, it has been described that several causal variants 
exist in a single LD block, located in multiple enhancers that cooperatively influence 
gene expression (the so called super-enhancers) [34,47]. These enhancer clusters are 
highly cell type specific. In this respect, although publicly available datasets [34,35] did 
not consider the C7ORF76 genomic region to be a super-enhancer, the functional 
annotation of this region revealed the presence of several putative regulatory elements 
containing SNPs prone to confer susceptibility to osteoporosis. 
To elucidate the molecular mechanisms underlying the strong association, further 
exploration with high-coverage sequencing to prioritise potentially causal variants was 
necessary [48]. We performed an extreme-truncate selection of the BARCOS cohort as 
a discovery phase, prior to genotyping the selected variants in the complete cohort. 
The efficiency of extreme-truncate selection approach for quantitative trait association 
studies (e.g. BMD) has been widely proven, as well as its utility for detecting rare 
variants [6,49,50]. The 2 SNPs found associated in the BARCOS cohort in this study 
(rs4342521 and rs10085588) were previously found associated with LS-BMD, FN-BMD 
and osteoporotic fracture in other GWAS studies [4,9]. In contrast, we failed to find 














have been found associated with LS-BMD, FN-BMD, and osteoporotic fracture [6,8,16], 
as well as with heel BMD [10,12] and total body BMD [11].  Taken together, these 
association data are consistent with the existence of a large LD block encompassing all 
the associated variants and the comparatively small sample size of the BARCOS 
cohort may preclude the detection of some of them. 
To further delineate the role of the three associated variants (the two mentioned above 
and the GWAS SNP in Estrada et al. [7]), we performed cis-eQTL analyses in human 
primary osteoblasts and we detected a nominal association between the minor alleles 
of the three SNPs and decreased SLC25A13 gene expression. We also detected a 
trend for association with decreased expression of SHFM1. These results reflect the 
LD among the SNPs. We failed to find an association between SNP rs10429035 and 
transcription levels of SHFM1, while in GTEx this SNP is described as eQTL for this 
gene in tibial artery. It could be that it is not eQTL in primary osteoblasts. Alternatively, 
our limited power (n=45) and the fact that primary cells are not as homogeneous as cell 
lines may have prevented us to detect it in primary osteoblasts [51].  
Out of the 3 associated SNPs, only one lies within a regulatory region (UPE, see Fig. 
1), while the others map to sequences lacking regulatory marks. We set out to 
experimentally study the UPE, which is a conserved region located approximately 4 kb 
upstream of C7ORF76 TSS, with enhancer marks such as H3K27ac and H3K4me1, as 
well as a DNase hypersensitivity signal. According to ENCODE ChIP-seq data, many 
transcription factors bind to UPE, among which RAD21, MYC, POLR2A, and the P300 
histone acetyltransferase, known to be involved in transcription regulation, initiation and 
elongation and in enhancer activity [52,53]. Our results, including luciferase assays, 
RT-PCR and 4C analyses, indicate that, indeed, the UPE acts as a regulatory element, 
able to activate transcription of a reporter gene. It is well known that many such 
elements can be transcribed [54–56], producing non-coding RNAs (or eRNAs for 














Our results also provide clear evidence that SNP rs10085588, within the UPE, is itself 
functional, since we showed that the minor allele (A) abolished luciferase activation, 
which was otherwise stimulated by the major allele G. We have performed an in silico 
analysis and found predictions that the histone deacetylase HDAC2 may bind the A 
allele more probably than the G (p-value: 5.30016e-06), a possible explanation for the 
reduced expression observed.  
The 4C-seq experiments showed that, in the cells included in this study, the UPE 
interacted with several sites within the TAD where it belongs (see Fig. 4), and nowhere 
else in the genome. This suggests that the biological function of the GWAS signal 
should be limited to genes within this TAD, further supported by strong CTCF signals 
limiting the region. However, interactions with other genomic regions may exist in 
different tissues or differentiation stages, not tested by us. In this sense and 
interestingly, a computationally-based characterization of osteoporosis associated 
SNPs identified an interaction between the GWAS SNP rs4729260 in the C7ORF76 
region and the Xq12 genomic region [57], which contains the androgen receptor gene, 
known to be involved in bone metabolism [58].  
Within the TAD, the UPE enhancer interacted with many other tissue-specific 
enhancers previously identified [42,43], suggesting that they may act cooperatively or 
redundantly in regulating gene expression. Several of these enhancers have been 
shown to affect DLX5/6 gene expression [43]. However, we have not detected strong 
interaction signals with the DLX5/6 region and, in our eQTL study in primary 
osteoblasts, we did not observe any effect of the associated SNPs on DLX5/6 gene 
expression. Likewise, we detected modest interactions between the UPE and the 
SHFM1 and the SLC25A13 coding regions, and negligible signals with that of 
DYNC1I1. In contrast, we did detect a marked interaction with a lncRNA in the close 
vicinity of C7ORF76, namely LOC100506136. Interestingly, a recent study found a 
SNP within LOC100506136 to be one of the 2 out of approximately 55,000 genome-














found a LS-BMD associated signal within LOC100506136 in a Mexican-Mestizo cohort 
[60]. These studies suggest that this lncRNA could be involved in osteoporosis 
pathogenesis.  
This work has some limitations including the sample size of the BARCOS cohort, and 
of the primary osteoblasts used for the eQTL analyses, both of which preclude the 
detection of variants with smaller effects. In addition, C7ORF76 was not tested in other 
bone cells such as osteoclasts. However, these results provide interesting data to 
understand the functionality of this unexplored region, one of the most frequently found 
associated with osteoporosis in GWA studies. They also highlight the importance of 
regulatory variants in bone phenotypes and the usefulness of integrative approaches to 




In summary, this study is the first one to analyse in depth the functionality of the 
C7ORF76 genomic region, associated with BMD and osteoporotic fracture in many 
GWAS. We provide functional regulatory evidence for the rs10085588, which may be a 
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 Table 1. Number and location of single nucleotide variants found in this study  














Common variants 96 51 0 12 3 1 
LFV 24243 59 1 16 1 0 











Table 2. Association between common and LFV variants of C7ORF76 and LS-BMD, FN-BMD or osteoporotic fracture  
 
Values in bold indicate statistical significance; values in italics indicate nominal significance 
aSNP found monomorphic in the BARCOS cohort 
bSNP previously genotyped in the BARCOS cohort (Estrada et al. [7]) 










(β coeff; 95% CI) 
p-value FN-BMD 
Effect size 
(β coeff; 95% CI) 
p-value osteoporotic fracture Effect size 
(OR; 95% 
CI) 











5’UP 0.00361 0.00343 0.05032 
-0.0324 (-
0.0541, -0.0108) 






5’UP 0.00314 0.00251 0.05233 
-0.0332 (-
0.0547, -0.0117) 
























I 0.00141 0.00207 0.02430 
-0.0362 (-
0.0592, -0.0132) 
0.06943 0.04540 0.27708 
-0.0175 (-0.0345, -
0.0004) 
































Table 3. cis-eQTL analysis of 3 C7ORF76 variants associated with BMD 
Values in italics indicate nominal significance 
*p-values are identical as a reflection of the high LD between the 2 SNPs 
  
 p-values 
SNP DLX5 DLX6 DLX6-AS1 SHFM1 SLC25A13 
rs10085588 0.14207 0.53849 0.59125 0.05270 0.03350 
rs4342521* 0.09227 0.34167 0.55062 0.05725 0.01442 















Fig. 1. Schema of C7ORF76 locus. In green, region re-sequenced in the present study. 
In dark red, SNPs genotyped in the BARCOS cohort and in bold, SNPs found 
associated with BMD; # SNP previously genotyped (Estrada et al. [7]). Transcription 
factor ChIP-seq, DNase HS, H2A.Z, H3K4me1, H3K27ac, H3K4me2 and H3K4me3 
ChIP-seq from osteoblasts (ENCODE), and vertebrate conservation are shown. The 
red boxes represent putative regulatory elements, according to epigenetic marks as 
well as transcription factors binding. Note that V-Enh corresponds to an enhancer 
(hs211) described in VISTA Enhancers database [42]. PRE1=putative regulatory 
element 1; PRE2=putative regulatory element 2; V-Enh=VISTA enhancer hs2311; 
UPE=4kb upstream putative regulatory element. 
 
Fig. 2. Linkage disequilibrium plot of C7ORF76 genotyped variants. *GWAS hit from 
Estrada et al. [7]. The numbers within the squares and the colour scale both refer to 
D’/LOD values (with bright red: D'=1 and LOD≥2; white: D'<1 and LOD<2; blue: D’=1 
and LOD<2 and shades of pink/red: D’<1 and LOD ≥2). 
 
Fig. 3. (A) Luciferase activity of different versions of UPE, containing the G or A allele 
for the SNP rs10085588, in a forward or inversed orientation, in Saos-2 cells. Results 
are expressed as mean±SD. **p-value<0.01; ***p-value<0.001 (B) PCR amplification of 
UPE from cDNA of different cell types. Expected size: 750 bp. 
 
Fig. 4. 4C-seq using UPE as viewpoint in human fetal osteoblast (hFOB) 1.19, 
mesenchymal stem cells (MCS) and Saos-2 cell line. H2A.Z, H3K4me1, H3K27ac and 
CTCF ChIP-seq and DNase HS from osteoblasts (ENCODE data), and vertebrate 
conservation are shown. Experimentally validated active enhancers from VISTA 
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 Two SNPs in the C7ORF76 genomic region (rs4342521 and rs10085588) were 
statistically associated with BMD in the BARCOS cohort 
 rs4342521, rs10085588 and rs4727338 may be eQTLs of SLC25A13 on human 
primary osteoblasts 
 A regulatory element containing rs10085588 (UPE) is able to stimulate 
transcription in an allele-dependent manner 
 UPE interacts with other enhancers in the region and with a lncRNA previously 
found associated with BMD 
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